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Abstract 
BACKGROUND: Diffuse astrocytomas constitute the largest group of primary malignant human intracranial 
tumours. They are classified by the World Health Organization (WHO) into three histological malignancy grades: 
diffuse astrocytomas (grade II), anaplastic astrocytomas (grade III) and glioblastoma (grade IV) based on 
histopathological features such as cellular atypia, mitotic activity, necrosis and microvascular proliferation. 
Epidermal growth factor receptor (EGFR) is a 170-kDa transmembrane tyrosine kinase receptor expressed in a 
variety of normal and malignant cells regulating critical cellular processes. When activated, epidermal growth 
factor receptor (EGFR) triggers several signalling cascades leading to increased proliferation and angiogenesis 
and decreased apoptosis and hence associated with aggressive progression of the tumour. Epidermal growth 
factor receptor (EGFR) level is known to be a strong indicator associated with the aggressive behaviour of the 
tumour and acts as a prognostic factor for evaluating the survival rate. 
AIM: To evaluate the expression of epidermal growth factor receptor (EGFR) in different grades of astrocytoma.  
MATERIAL AND METHODS: formalin-fixed paraffin-embedded astrocytic tumours of 44 patients were collected 
from the archival material of pathology department of Ghazi Al Hariri Teaching Hospital during the period from 
June to December 2018. Hematoxylin and eosin-stained sections were used to characterise the tumours 
histologically based on cellularity, nuclear hyperchromasia, polymorphism, mitotic activity, vascular proliferation 
and necrosis with or without pseudopallisading of tumour cells. Diagnosis and grading of astrocytic tumours in this 
study were made according to WHO criteria (2016). Using a monoclonal antibody to the epidermal growth factor 
receptor (EGFR) and immunohistochemical analysis, the expression and distribution of epidermal growth factor 
receptor in astrocytic tumours were examined. 
RESULTS: The study included 1 case pilocytic astrocytoma (grade I), 20 cases diffuse astrocytoma (grade II), 5 
cases anaplastic astrocytoma (grade III) and 18 cases of glioblastoma (grade IV). Expression of EGFR was found 
in 38.88% of the glioblastoma samples (grade IV). However, none of the astrocytomas of WHO grades I, II and III 
showed immunoreactivity for EGFR protein. Different patterns of immunoreactive cells and significant intratumor 
heterogeneity of EGFR expression were observed in glioblastomas. 
CONCLUSION: The immunohistochemical expression of Epidermal growth factor receptor (EGFR) was restricted 
only to high-grade astrocytic tumours, namely glioblastoma, thus may use to predict glioblastoma. 
 
 
 
 
Introduction 
 
Primary brain tumours are a heterogeneous 
group of benign and malignant tumours arising from 
the brain parenchyma and its surrounding structures. 
These tumours are an important cause of morbidity 
and mortality in both adults and children, often 
generating severe disabilities and producing high 
burden in both families and health care systems [1], 
[2]. 
The world age-standardized incidence rate for 
all primary brain tumours ranged from 4.3 to 18.6 per 
100 000 per year [3].
 
In the United States, the incidence rate for 
primary brain and nervous system tumours in adults 
(aged 20 years or older) is estimated to be 29.9 per 
100,000 persons (data from 52 cancer registries, 2011 
to 2015) [4]. Approximately one-third of tumours are 
malignant and the remainder is benign or borderline 
malignant [4], [5].
 
Gliomas are tumours of the brain parenchyma 
that are classified histologically based on their 
resemblance to different types of glial cells. The major 
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types of glial tumours are astrocytoma, 
oligodendrogliomas, and ependymomas [6], [7]. 
The WHO classification and grading of CNS 
tumours recognise seven sub-types of astrocytic 
neoplasms grouped into two major categories. These 
include diffusely invasive astrocytoma (diffuse 
astrocytoma, anaplastic astrocytoma, glioblastoma) 
and the relatively more circumscribed tumours 
(pilocytic and pilomyxoid astrocytoma, pleomorphic 
xanthoastrocytoma, subependymal giant cell 
astrocytoma). 
The so-called ‘gliomatosis cerebri’, a 
clinicopathologic and radiologic entity, is also a diffuse 
glioma, usually of the astrocytic type [8], [9]. 
Diffuse astrocytomas (WHO grades II to IV) 
account for roughly 40% of primary intracranial 
tumours, with an annual incidence of 4 per 100,000 
person-years. They occur at all ages, although the 
median age is 30 to 40 for astrocytoma (grade II), 40 
to 50 years for anaplastic astrocytoma (grade III), and 
50 to 60 years for glioblastoma (grade IV). 
Glioblastomas are the most frequent, with low-grade 
examples being comparatively uncommon, particularly 
in the elderly [10]. 
The origin of astrocytic neoplasms may 
include neural stem cells, progenitor cells, or 
differentiated glial cells.  
Many molecular markers used as prognostic 
markers in glioma these include IDH mutations, 
1p/19q codeletion, MGMT promoter methylation, 
TERT promoter mutations and EGFR amplification 
[11]. 
Isocitrate dehydrogenase (IDH1, IDH2) and 
TP53 gene mutations are considered to be early 
events in neoplastic progression. In contrast, allelic 
loss of chromosome 10 occurs predominantly in 
glioblastomas. Molecular genetic studies have 
revealed differences between glioblastomas that 
evolve over the years from low-grade astrocytoma 
(secondary) and those that arise de novo (primary). In 
particular, Epidermal growth factor receptor (EGFR) 
overexpression is common in primary glioblastoma, 
while IDH1 mutations are common in secondary 
glioblastoma [12]. 
Epidermal growth factor (EGF) and the 
epidermal growth factor receptor (EGFR) have long 
been recognised for their role in tumour growth [13]. 
There are four transmembrane epidermal growth 
factor receptors: EGFR (also known as human EGF 
receptor 1 or HER1), HER2, HER3, and HER4 [14]. 
The EGFR protein contains an extracellular 
ligand-binding domain, a transmembrane region and 
an intracellular domain with intrinsic protein-tyrosine 
kinase activity. Ligand binding of the EGF receptor 
activates the EGFR tyrosine kinase which 
phosphorylates proteins in the signal transduction 
pathway leading to activation of genes that regulate 
cell proliferation, angiogenesis, motility, and 
metastasis [15], [16].
 
In astrocytoma, overexpression of EGFR or 
ErbB1 (chromosome 7p11-p12) is a late event 
promoting malignant progression to a glioblastoma, 
with amplification and often accompanying activating 
mutations. EGFR amplification varying in ranges of 0-
4%, 0-33% and 34%-64% in grade II, III and IV 
astrocytomas, respectively. This amplification 
correlated to the histological malignancy grade and 
lower overall survival [17], [18], [19], [20], [21]. 
It has been shown that EGFR amplification 
promotes invasion, proliferation and resistance to 
radiotherapy and chemotherapy [22], [23], [24], [25]. 
We aimed to evaluate the expression of 
epidermal growth factor receptor (EGFR) in different 
grades of astrocytoma in a sample of Iraqi patients. 
 
 
Material and Methods 
 
This cross-sectional study enrolled 44 
formalin-fixed paraffin-embedded astrocytic tumours, 
17 were females and 27 were males diagnosed with 
different grades of astrocytic tumours of which 1 case 
was Pilocytic astrocytoma grade I, 20 cases were 
diffuse astrocytoma grade II (18 cases were diffuse 
fibrillary astrocytoma and 2 cases were pleomorphic 
xanthoastrocytoma), 5 cases were anaplastic 
astrocytoma grade III and 18 cases were glioblastoma 
grade IV. Graded according to WHO criteria 2016 
[26]. These cases were retrieved from the archival 
material of pathology department of Ghazi Al Hariri 
Teaching Hospital during the period from June to 
December 2018. 
All the clinical information, including age, 
gender and location, had been taken from patients 
archive files. 
All biopsies were obtained through open brain 
biopsy, from each paraffin block, 2 representative (4 
micrometres) sections were obtained, one section 
stained with hematoxylin and eosin stain and 
characterized on the basis of cellularity, nuclear 
hyperchromasia, polymorphism, mitotic activity, 
vascular proliferation and necrosis with or without 
pseudo pallisading of tumor cells into different grades 
and the other section was subjected to 
immunohistochemical testing for Anti- EGFR antibody, 
clone (EP38Y) manufactured by Abcam dilution 
(1:100). 
 
Interpretation of the results of IHC staining 
Immunoreactivity was scored based on 
membranous and / or cytoplasmic staining [27]. 
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 A positive stain is indicated by a golden 
brown coloured precipitate at the site of specific 
cellular antigen localisation. 
The positive control for EGFR was obtained 
from tonsillar tissue sections, which are known to 
express EGFR in its basilar squamous epithelial cells 
was used with each run. 
Technical negative control was obtained by 
omission of the primary antibody (EGFR). 
 
Scoring system 
Immunohistochemical stains for EGFR were 
graded as follows: 0 (no cell stained), 1 + (< 5% tumor 
cells stained), 2 + (5- 50% cells stained), and 3 + (> 
50% cells stained). For statistical analysis, a score of 
0 and 1 were considered negative and a score of 2 or 
3 was considered positive [28]. 
All statistical analyses were performed using 
SPSS ver. 19.0 (SPSS Inc., Chicago, IL, USA). 
Univariate data were summarised using standard 
descriptive statistics, tabulation of categorical 
variables and histograms of numerical variables. 
Associations between categorical variables were 
assessed via cross-tabulation and chi-square. T-test 
and ANOVA were used to compare means of 
continuous variables.  
Spearman correlation was used to measure 
the association between two continuous variables or 
when at least one variable was ordered. Exact tests 
were used to calculate the p value. A p-value of less 
than 0.05 was accepted as statistically significant. 
 
 
Results 
 
Frequency distribution of different grades 
 of astrocytoma 
Histopathological review of primary brain 
astrocytic tumours involved in this study revealed the 
following: 
 The highest frequency was noticed in low-
grade astrocytoma (grade II) which constituted 20 
cases (45.45%), (18 cases were diffuse fibrillary 
astrocytoma and 2 cases were pleomorphic 
xanthoastrocytoma), followed by glioblastoma (grade 
IV) which constituted 18 cases (40.9%), anaplastic 
astrocytoma (grade III) which constituted 5 cases 
(11.36%) and pilocytic astrocytoma (grade I) with only 
one case (2.27%) according to WHO criteria 2016 
[11].  
Among cases with glioblastoma, the majority 
was primary15 (83.33%), and only 3(16.7%) were 
secondary (progress from low grade astrocytoma) 
(Figure 1 and 3). 
 
Figure 1: Pie chart showing distribution of cases according to grade 
of astrocytoma 
 
Age group and sex distribution 
Distribution among age groups revealed that 
the mean age of cases in this study was 37.41 ± 
19.02 year. 
The mean age of patients with grade IV 
astrocytoma was 44 ± 17.92 year, grade III 44.4 ± 
6.66 year, grade II 30.95 ± 19.56 year and grade I 13 
year with no statistically significant difference (p value 
= 0.073) (Table 1). 
Table 1: Mean age of different grades of astrocytoma in the 
studied cases 
Tumor Grade Mean Age (year) P value 
Grade-I 13 0.073 (N.S) 
Grade-II 30.95 ± 19.56 
Grade-III 44.4 ± 6.66 
Grade-IV 44 ± 17.92 
TOTAL 27 (61.4) 
 
Males constituted 61.4% of total cases. 
Differences between males and females among 
different grades of astrocytic tumors showed the 
following: males constituted 9/18 (50%) of patients 
with grade IV, 4/5 (80%) of patients with grade III, and 
14/20 (70%) of patients with grade II with no 
statistically significant difference (p value = 0.3) (Table 
2). 
Table 2: Distribution of different grades of astrocytoma 
according to the gender of the studied cases 
Tumor Grade Males No. (%) Females No. (%) P value 
Grade-I 0 (0) 1(100) 0.3 (N.S) 
Grade-II 14 (70) 6 (30) 
Grade-III 4 (80) 1 (20) 
Grade-IV 9 (50) 9 (50) 
 Total 27 (61.4) 17 (38.6) 
 
Epidermal growth factor receptor (EGFR) 
 immunohistochemical expression 
EGFR expression was positive in 7 (15.9%) of 
the cases, all of which were of grade IV astrocytoma. 
All cases of grade I, II, III were negative for EGFR 
expression 37 (84.1%) of the cases (Figures 2and 3). 
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Figure 2: Pie chart showing the distribution of the cases according 
to the immunohistochemical expression of EGFR 
 
Immunohistochemical expression of EGFR 
was seen only among those with glioblastoma, 7/18 
cases showed EGFR expression (38.88%) as shown 
in Table 3, four were females (57.7%), and three were 
males (42.85%) with a mean age of 46.71 years. 
Table 3: EGFR immunohistochemical expression according to 
the grade of astrocytoma 
Tumour No. of positive cases EGFR expression % 
Pilocyte astrocytoma grade I 0 / 1 0% 
Diffuse astrocytoma grade II 0 / 20 0% 
Anaplastic astrocytoma III 0 / 5 0% 
Glioblastoma IV 7 / 18 38.88% 
Total 44  
 
Immunohistochemical expression of EGFR 
 according to the age of the studied cases 
The mean age of those with 
immunohistochemical expression of EGFR was 46.71 
years, whereas the mean age of negative cases was 
35.64 years. The difference was statistically significant 
(P-value = 0.04). Within grade IV astrocytoma, the 
mean age of negative cases was 42.27 years 
compared to 46.71 years for the positive cases. The 
difference was statistically insignificant (P-value = 
0.06) (Table 4). 
Table 4: Association between immunohistochemical 
expression of EGFR and Age 
Tumour No. Mean 
age (year) 
P-value 
Astrcytomas with positive expression of EGFR (all grades)  7 46.71 0.04 
Astrocytomas with negative expression of EGFR (all grades)  37 35.64 
Glioblastomas with positive expression of EGFR  7 46.71 0.06 
Glioblastomas with negative expression of EGFR  11 42.27 
 
Within grade IV astrocytoma, males 
constituted 3 cases (42.85%) of EGFR-positive cases 
and 6 cases (54.54%) of EGFR-negative cases. 
 
The difference in sex regarding EGFR 
positivity was statistically insignificant (P-value = 0.45) 
(Table 5). 
Table 5: Immunohistochemical expression of EGFR according 
to the gender of the patient with glioblastoma 
EGFR expression in glioblastoma Gender 
Total 
P-value 
M
al
e 
Female 
0.45 NS 
Positive 3 4 7 
Negative 6 5 11 
Total 9 9 18 
a)
 
b)
 
c)
 
d)
 
e)
 
f)
 
Figure 3: a) Pilocytic astrocytoma shows Rosenthal fibres, note 
homogenous eosinophilic staining (H & E × 10); b) Anaplastic 
astrocytoma, grade III. This lesion exhibits increased cellularity, the 
cytological features of a fully malignant neoplasm (H & E × 400); c) 
Glioblastoma grade IV, H & E, (x 400); d) Diffuse fibrillary 
astrocytoma, grade II with negative immunohistochemical 
expression of EGFR IHC (x 400); e) Anaplastic astrocytoma, grade 
III with negative IHC expression of EGFR (x 400); f) Glioblastoma 
(grade IV) stained with anti-EGFR showing positive staining for 
EGFR (complete membranous and cytoplasmic staining) + 3 (× 
400) 
 
 
Discussion 
 
Epidermal growth factor and its receptor 
(EGFR) constitute an important and well-
characterized mitogenic system in various ectodermal 
tissues, including glial cells.  
Over-expression of the EGFR due to gene 
amplification has been reported in primary brain 
tumours of glial origin [29]. This amplification 
promotes invasion, proliferation and resistance to 
radiotherapy and chemotherapy thus correlated to the 
histological malignancy grade and lower overall 
survival [17], [18], [19], [20], [21], [22], [23], [24], [25]. 
Based on these features, this marker chooses in this 
study to predict high-grade astrocytoma.  
Astrocytic tumours begin as early as in the 
first decade of life. Young adults are typically affected 
by low-grade astrocytoma while glioblastoma shows a 
peak incidence in the sixth decade. Anaplastic 
astrocytoma occupies an intermediate position [30]. 
Glioblastoma is among the most malignant human 
neoplasms with a mean duration of survival for less 
than one year.  
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Extensive research works on the molecular 
pathogenesis of glioblastoma may facilitate molecular 
classification of this tumour and predict prognostic 
markers. 
Expression of EGFR is important in molecular 
classification and is considered as a new prognostic 
parameter for astrocytic tumors [20], [31], [32], [33]. 
The current study showed that astrocytic 
tumours are more common in males than in females, 
61.4% compared to 38.6%. The mean age of patients 
was (37.41 ± 19.02) year. The mean age of patients 
with grade IV and grade III astrocytoma was higher 
than that of patients with grade I and II astrocytoma; 
However, these findings were of no statistical 
significance. 
Several previous studies found similar 
findings regarding the male predominance and mean 
of age; in Chaloob et al., study the mean age for 
cases of astrocytoma was 35.98 ± 2.67 years, they 
also found slight male predominance (53%) compared 
to females (47%) in astrocytoma [30]. 
Maiti et al., in their study, found that males 
constituted 58% of cases with a mean age of 42 ± 13 
years [31]. Kordek et al. showed that males 
constituted 56% of cases with a mean age of 45 ± 11 
years [32]. In Agosti et al., study, males constituted 
64% of cases and the mean age was 34 ± 14 years 
[29].  
In this study, the majority of cases were of 
grade II (45.5%) followed by grade IV (40.9%), 
similarly, Chaloob et al., found in their study that 
grade II is the most frequent: 7 (13.2%) cases were 
grade I, 22 (43.1%) cases were grade II, 6 (11.8%) 
cases were grade III and 16 (31.4%) cases were 
glioblastomas (grade IV) [30]. On the other hand, 
other studies showed different findings, Agosti et al. 
showed that out of 103 cases with astrocytoma, 21 
cases were of grade I, 10 cases of grade II, 26 cases 
of grade III, and the most frequent were of grade IV 
(46 cases) [29]. 
Similarly, Maiti et al., in their study that 
included 40 cases of astrocytoma found that 21 cases 
were of glioblastoma or Grade IV astrocytoma 
(52.5%), eight cases of anaplastic astrocytoma or 
Grade III astrocytoma (20%), six cases of diffuse 
Grade II astrocytoma (15%) and five cases were 
grade I (12.5%) [31]. In Kordek et al., study of 56 
cases of astrocytoma, 8 cases were of pilocytic (grade 
I) astrocytoma, 9 cases were of grade (II) fibrillary 
astrocytoma, 9 cases were of high grade (III) 
anaplastic astrocytoma and the majority of the cases 
(30) of glioblastomas (grade IV) [32]. Gaitonde et al. 
showed in their study that out of 30 cases with 
astrocytoma, 2 cases were of grade I-II, 11 cases 
were of the anaplastic type, 13 cases were of 
glioblastoma type and 4 cases were of other 
histological types [33].  
This difference in grade frequency among 
different studies may suggest geographical or 
environmental causes as Iraqi studies show the 
predominance of grade II while worldwide studies 
reveal grade IV predominance 
EGFR amplification is rare in low-grade 
gliomas [32], [33], [34], [35], [36] however, many 
studies have reported EGFR amplification varying in 
ranges of 0-4%, 0-33% and 34%-64% in grade II, III 
and IV astrocytomas, respectively [17], [18], [19], [20], 
[21]. 
In the recent study, EGFR expression was 
found in only 7 (38.88%) cases of glioblastomas, while 
it was negative in all other types, these findings 
Although other similar studies showed EGFR 
expression in other grades of astrocytoma, still the 
expression was higher in higher grades. Kordek et al. 
showed that 23% of astrocytoma express EGFR and 
that the immunohistochemical expression of EGFR 
increased with the grade of malignancy (11.1%, 
22.2% and 33.3%) [32]. Gaitonde et al. showed 
positive EGFR expression in 8 of 30 cases of 
astrocytoma [33]. Gines et al. found that 53% of 
primary glioblastoma showed EGFR amplification and 
33% of them showed EGFR over-expression [36]. 
Smith et al., showed that EGFR amplification was 
present in 17% of anaplastic astrocytoma and 41% of 
glioblastomas [20].  
Stark et al. showed that 64% of glioblastoma 
showed positive EGFR expression [37]. 
Maiti et al., and van der Valk et al., in their 
study, showed that all cases of grade I astrocytoma 
showed negative immunostaining for EGFR [31], [38]. 
However, EGFR positivity has been observed in 
Grades II-IV with increasing expression associated 
with higher grades of astrocytoma [38]. These results 
were in agreement with those reported by Smith et al., 
in their study [20].  
Shinojima et al. found that overexpression of 
EGFR and gene amplification frequently occurs in 
gliomas and is restricted to high-grade tumours, 
especially anaplastic astrocytoma and glioblastoma 
multiforme [19]. In this study, there was a significant 
association between immunohistochemical expression 
of EGFR and age of the patients with the mean age of 
cases with positive expression significantly higher 
than cases with negative expression; this may be 
attributable to that the mean age of the patient with 
glioblastoma is higher where EGFR is over-
expressed. Within grade IV astrocytoma, there was no 
statistically significant association between positive 
EGFR expression and age of patients, these findings 
wherein tune with that of Maiti et al., Stark et al., and 
Bouvier et al., [31], [37], [39]. 
On the other hand, Kordek et al., showed that 
higher expression was associated with a younger age 
group [32]. Smith et al., and Van der Valk et al., 
showed no significant association of EGFR 
expression with specific age group [20], [38]. 
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Taking gender of the study sample into 
consideration, the current study reported no significant 
association of EGFR expression with the sex of the 
patients even within those who expressed the EGFR 
that is in unity with other authors; Maiti et al., and 
Kordek et al., [31], [32]. On the other hand, Bouvier et 
al., and Torp et al., showed higher expression of 
EGFR among female [39], [40], while Smith et al., and 
Agosti et al., showed more positive EGFR expression 
in male patients [20], [29]. These differences in 
relations with age and sex may be due to differences 
in sample size. 
In conclusion, the immunohistochemical 
expression of Epidermal growth factor receptor 
(EGFR) was restricted only to glioblastoma, thus may 
use to predict a high-grade glioblastoma.  
EGFR expressed in 38.8% of glioblastoma 
patients which means 38.8% of these patients tend to 
arise de novo as primary glioblastoma. 
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